These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9410682)

  • 1. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
    Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
    Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
    Haier J; Hohenberger P; Beck K; Schlag PM
    Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
    Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen.
    Hohenberger P; Haier J; Schlag PM
    Eur J Cancer; 1997 Apr; 33(4):596-601. PubMed ID: 9274441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procalcitonin as marker of systemic inflammatory reaction after isolated extremity perfusion].
    Kettelhack C; Hohenberger P; Furchtbar S; Schulze G; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):399-402. PubMed ID: 14518284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
    Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
    J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
    Hohenberger P; Bida B; Schlag PM
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
    [No Abstract]   [Full Text] [Related]  

  • 13. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
    Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
    Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and morbidity of isolated limb perfusion.
    Vrouenraets BC; Klaase JM; Nieweg OE; Kroon BB
    Semin Surg Oncol; 1998; 14(3):224-31. PubMed ID: 9548605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.